Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Cancer medicines on the WHO Model List of Essential Medicines: processes, challenges, and a way forward
Kristina Jenei, Zeba Aziz, Christopher M. Booth, et al.
The Lancet Global Health (2022) Vol. 10, Iss. 12, pp. e1860-e1866
Open Access | Times Cited: 34

Showing 1-25 of 34 citing articles:

High Cost of Chimeric Antigen Receptor T-Cells: Challenges and Solutions
Edward R. Scheffer Cliff, Amar H. Kelkar, David A. Russler‐Germain, et al.
American Society of Clinical Oncology Educational Book (2023), Iss. 43
Open Access | Times Cited: 47
Uptake of orphan drugs in the WHO essential medicines lists
Enrico Costa, Lorenzo Moja, Veronika J. Wirtz, et al.
Bulletin of the World Health Organization (2024) Vol. 102, Iss. 1, pp. 22-31
Open Access | Times Cited: 7
Distinguishing Clinical From Statistical Significances in Contemporary Comparative Effectiveness Research
Ajami Gikandi, Julie Hallet, Bas Groot Koerkamp, et al.
Annals of Surgery (2024)
Closed Access | Times Cited: 7
Etoposide as a Key Therapeutic Agent in Lung Cancer: Mechanisms, Efficacy, and Emerging Strategies
Jung Yoon Jang, Donghwan Kim, Eunok Im, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 2, pp. 796-796
Open Access
Breast Cancer-the-State-of-the Art in the World and Islamic Development Banks Members Countries (IsDB-MCs)
Ahmed A. M. Elnour
(2025), pp. 169-213
Closed Access
Green synthesis and in vitro anticancer evaluation of 1,2-disubstituted benzimidazole derivatives
Alcives Avila‐Sorrosa, Luis Ángel Gil-Ruiz, Marı́a Elena Vargas-Dı́az, et al.
Results in Chemistry (2025), pp. 102134-102134
Open Access
The Political Economy of the World Health Organization Model Lists of Essential Medicines
Kristina Jenei
Milbank Quarterly (2025)
Open Access
Expanding access to biotherapeutics in low-income and middle-income countries through public health non-exclusive voluntary intellectual property licensing: considerations, requirements, and opportunities
Sébastien Morin, Giulia Segafredo, Manuele Piccolis, et al.
The Lancet Global Health (2022) Vol. 11, Iss. 1, pp. e145-e154
Closed Access | Times Cited: 26
Source, Occurrence, and Risk Assessment of Antineoplastic Medicines in Aquatic Environments: A Comprehensive Review
Ankush Yadav, Eldon R. Rene, Manisha Sharma, et al.
Current Pollution Reports (2023) Vol. 9, Iss. 3, pp. 391-409
Closed Access | Times Cited: 14
Cancer medicines: a private vice for public benefit?
Richard Sullivan
ecancermedicalscience (2024) Vol. 18
Open Access | Times Cited: 3
Unification of Efforts to Improve Global Access to Cancer Therapeutics: Report From the 2022/2023 Access to Essential Cancer Medicines Stakeholder Summit
Edward L. Briercheck, Doug Pyle, Cary Adams, et al.
JCO Global Oncology (2024), Iss. 10
Closed Access | Times Cited: 3
Mechanistic insight and structure activity relationship of isatin-based derivatives in development of anti-breast cancer agents
Atamjit Singh, Karanvir Singh, Aman Sharma, et al.
Molecular and Cellular Biochemistry (2023) Vol. 479, Iss. 5, pp. 1165-1198
Closed Access | Times Cited: 8
Refocusing the World Health Organization’s Model List of Essential Medicines on the needs of low and middle income countries
Veronika J. Wirtz, Andy Gray, Sangeeta Sharma, et al.
BMJ (2024), pp. e077776-e077776
Closed Access | Times Cited: 2
Perspectives on organ-on-a-chip technology for natural products evaluation
Xin Wang, Yu‐Hang Miao, Xiaomin Zhao, et al.
Food & medicine homology. (2024) Vol. 1, Iss. 2, pp. 9420013-9420013
Open Access | Times Cited: 2
Adherence, clinical benefits, and adverse effects of endocrine therapies among women with nonmetastatic breast cancer in developing countries: A systematic review and meta‐analysis
Shaimaa Elshafie, Rupal Trivedi, Lorenzo Villa‐Zapata, et al.
Cancer (2024)
Open Access | Times Cited: 2
WHO Model list of essential medicines: visions for the future
Thomas Piggott, Lorenzo Moja, Benedikt Huttner, et al.
Bulletin of the World Health Organization (2024) Vol. 102, Iss. 10, pp. 722-729
Open Access | Times Cited: 2
An Overview of Head and Neck Tumor Reirradiation: What Has Been Achieved So Far?
Константин Гордон, Даниил Смык, И. А. Гулидов, et al.
Cancers (2023) Vol. 15, Iss. 17, pp. 4409-4409
Open Access | Times Cited: 7
Supporting Circular Economy Through Using Digital Transformation in Sustainable Pharmaceutical Reverse Logistics: Multi-objective Bi-level Modeling
Mahdi Alimohammadi, J. Behnamian
Process Integration and Optimization for Sustainability (2024)
Closed Access | Times Cited: 1
Global Cancer Drug Development—A Report From the 2022 Accelerating Anticancer Agent Development and Validation Meeting
Brooke E. Wilson, Richard Sullivan, Richard Peto, et al.
JCO Global Oncology (2023), Iss. 9
Open Access | Times Cited: 4
Assessment of anticancer drug utilization pattern and patients’ survival—A single center experience from Saudi Arabia
Ahmed M Badheeb, Manea Al Munjem, Faisal Ahmed, et al.
F1000Research (2024) Vol. 13, pp. 560-560
Open Access | Times Cited: 1
Global outlook on affordability of biotherapeutic drugs
Anurag S. Rathore, Peter J. Gardner, Hemlata Chhabra, et al.
Annals of the New York Academy of Sciences (2024) Vol. 1537, Iss. 1, pp. 168-178
Closed Access | Times Cited: 1
Ensuring Global Access to Cancer Medicines: A Generational Call to Action
Anna Dare, Arnaud Bayle, Asma Hatoqai, et al.
Cancer Discovery (2023) Vol. 13, Iss. 2, pp. 269-274
Open Access | Times Cited: 3
Availability and affordability of anticancer medicines at cancer treating hospitals in Rwanda
Clement Rurangwa, Jerome Ndayisenga, Jurdas Sezirahiga, et al.
BMC Health Services Research (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 3
Treating metastatic pancreatic ductal adenocarcinoma: NALIRIFOX as new standard?
Marc G. Besselink, Johanna W. Wilmink
The Lancet (2023) Vol. 402, Iss. 10409, pp. 1217-1218
Closed Access | Times Cited: 3
GRADE Concept 7: Issues and Insights Linking Guideline Recommendations to Trustworthy Essential Medicine Lists
Thomas Piggott, Lorenzo Moja, Kristina Jenei, et al.
Journal of Clinical Epidemiology (2023) Vol. 166, pp. 111241-111241
Open Access | Times Cited: 3
Page 1 - Next Page

Scroll to top